ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...

The BCG Compression Tee is My Ultimate Must-Have Piece of Running Gear—And Costs Under $20

The BCG compression tee sees me through every type of workout: 400-meter repeats, tempo runs, hill sprints, as well as ...

ImmunityBio's Promising Advances in BCG Naïve NMIBC Treatment with ANKTIVA Plus BCG

Enrollment Progress in QUILT-2.005 The QUILT-2.005 trial aims to evaluate the efficacy of ANKTIVA® in conjunction with BCG in patients who have not previously received BCG treatment. As of January ...

BCG warns the era of ‘wait and see’ is dead as global risks hit all-time high

As global policy uncertainty hit its highest level in two decades in 2025, BCG warns firms' response to risk "is no longer ...

ImmunityBio shares climb as bladder cancer trial nears full enrollment, BLA submission expected by year-end

ImmunityBio’s IBRX QUILT-2.005 trial tops enrollment forecasts; BLA filing targeted by year-end after positive ANKTIVA+BCG ...
Oncology Nurse Advisor

BCG May Be Less Effective for Treating NMIBC Following UTUC Surgery

By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

ImmunityBio's Promising Advances in NMIBC Treatment: Enrollment Surpasses Expectations for ANKTIVA Plus BCG

The QUILT-2.005 trial is a randomized registrational study designed to evaluate the effectiveness of ANKTIVA® combined with BCG in BCG-naïve patients. As of January 2026, enrollment has surpassed 85%, ...
Forbes

BCG Against Coronavirus: Less Hype And More Evidence, Please

I was born and raised in India. On the day I was born, I am told I got my first jab, a vaccine called BCG (bacille Calmette-Guerin). Kids born in India today still get this vaccine. This century-old ...